Antifungal Management of Oral Candidiasis

Oral candidiasis, commonly known as oral thrush, arises from overgrowth of Candida species on the mucosal surfaces of the mouth. Management strategies span topical agents, systemic therapies and emerging delivery systems, aiming to eradicate fungal colonisation, disrupt biofilms and prevent recurrence. First-line topical therapies such as nystatin and miconazole provide high local concentrations with minimal systemic exposure, while systemic triazoles—including fluconazole, itraconazole and newer agents such as posaconazole—are reserved for refractory or disseminated infections. Echinocandins and lipid formulations of amphotericin B serve as intravenous options for severe cases. Treatment choice is guided by patient factors, drug interactions and resistance patterns. Recent advances focus on enhancing mucosal drug retention via mucoadhesive platforms, harnessing natural products with synergistic activity and mapping molecular mechanisms to overcome multidrug resistance. A holistic approach also addresses predisposing factors—such as denture hygiene, immunosuppression and xerostomia—to reduce relapse and improve quality of life.

Research from Nature Portfolio

A recent study has demonstrated that combining a natural polyphenol extract with zinc ions yields potent synergistic activity against Candida albicans. The combination not only inhibited planktonic growth at lower concentrations than either agent alone, but also significantly reduced biofilm biomass and thickness. Mechanistic investigations revealed that the paired treatment induces excess intracellular reactive oxygen species in both free-living and biofilm forms of C. albicans, suggesting a novel oxidative stress-mediated antifungal mechanism. These findings highlight the potential of utilising plant-derived compounds in combination with metal ions as an adjunct or alternative to conventional antifungal drugs.

Antifungal Management of Oral Candidiasis publication trend

The graph below shows the total number of articles in antifungal management of oral candidiasis across all publications each year (not limited to Nature Index journals).

Technical terms

Biofilm: A structured community of microorganisms enclosed in an extracellular matrix, adherent to mucosal surfaces and resistant to antifungal agents.

Triazoles: A class of systemic antifungal agents (e.g., fluconazole, itraconazole, posaconazole) that inhibit ergosterol synthesis in fungal cell membranes.

Echinocandins: Intravenous antifungals (e.g., caspofungin, anidulafungin) that inhibit synthesis of β-glucan, a key cell wall component of Candida.

Mucoadhesive delivery: A drug-delivery approach that enhances retention time on the oral mucosa, improving local drug concentration and therapeutic efficacy.

Minimum inhibitory concentration (MIC): The lowest concentration of an antifungal agent that prevents visible growth of a microorganism under laboratory conditions.

References

1. Therapeutic tools for oral candidiasis: Current and new antifungal drugs. Medicina Oral Patología Oral y Cirugia Bucal (2019).
2. Synergistic activity of pomegranate rind extract and Zn (II) against Candida albicans under planktonic and biofilm conditions, and a mechanistic insight based upon intracellular ROS induction. Scientific Reports (2022).
3. Nystatin Effectiveness in Oral Candidiasis Treatment: A Systematic Review & Meta-Analysis of Clinical Trials. Life (2022).
4. Comparative Efficacy of Antifungal Agents Used in the Treatment of Oropharyngeal Candidiasis among HIV-Infected Adults: A Systematic Review and Network Meta-Analysis. Journal of Fungi (2021).
5. Molecular Mapping of Antifungal Mechanisms Accessing Biomaterials and New Agents to Target Oral Candidiasis. International Journal of Molecular Sciences (2022).